Yohimbinos (Yohimbine Hydrochloride)

About the Product

Yohimbinos is a research compound from Driada Medical, containing Yohimbine Hydrochloride. Yohimbine is an indole alkaloid derived from the bark of the Pausinystalia yohimbe tree, native to Central and West Africa, though it can also be produced synthetically. Its chemical formula is C₂₁H₂₆N₂O₃·HCl, with a molecular weight of approximately 390.9 g/mol. It is a white to slightly yellowish, crystalline powder.

The compound is recognized primarily as a potent and selective α2-adrenergic receptor antagonist. This mechanism has positioned it as a standard tool for research into adrenergic signaling, metabolic regulation, and erectile function.

The product is intended for laboratory research use only and features an integrated QR code on the packaging for detailed product verification.

• Product Name: Yohimbinos (Yohimbine Hydrochloride)

• Brand: Driada Medical

• Form: Solution for research applications

• CAS Number: 65-19-0

• For Research Use Only.

Research Applications & Mechanism of Action

• α2-Adrenergic Receptor Antagonist: Yohimbine functions as a competitive antagonist at α2-adrenergic receptors. By blocking these presynaptic receptors, it inhibits the negative feedback mechanism that normally suppresses norepinephrine release, leading to increased synaptic levels of this neurotransmitter and enhanced sympathetic nervous system activity.

• Metabolic & Lipolysis Research: Due to its sympathomimetic effects, yohimbine is a compound of interest in research on energy metabolism and fat oxidation. It has been explored for its potential to promote lipolysis (fat breakdown) and as an adjuvant in weight loss research models, although these applications remain controversial. Current scientific evidence does not support its use for these purposes in a clinical context.

• Sexual Function Research: Yohimbine's mechanism of action on α2-adrenergic receptors in the corpus cavernosum leads to sustained engorgement of penile tissue, making it a useful tool for studying the physiology of erectile function. It has been used as a reference compound in research for erectile dysfunction, particularly in models of neurogenic or vascular causes.

• Neuroscience Research: Yohimbine has significant effects on the central nervous system. It is used in research to study anxiety, stress responses, and the hypothalamic-pituitary-adrenal (HPA) axis, as it can induce anxiety-like behaviors and increase the release of stress hormones such as cortisol. It also interacts with serotonin (5-HT1A, 5-HT1B, 5-HT1D) and dopamine (D2, D3) receptors, albeit with lower affinity, making it relevant for receptor pharmacology studies.

Research & Scientific Background

• Pharmacological Profile: Yohimbine is a complex and promiscuous compound. While its primary action is α2-adrenergic antagonism, it also exhibits moderate affinity for serotonin receptors and some affinity for dopamine receptors. At higher concentrations, it can act as an α1-agonist, leading to vasoconstriction and increased blood pressure, a dual action that complicates its effects. It can also bind to imidazoline I2 receptors, which are involved in blood pressure regulation.

• Pharmacokinetics: Yohimbine is rapidly absorbed following oral administration (absorption half-life ~10 min) and has a relatively short elimination half-life of approximately 30 minutes. However, its oral bioavailability is highly variable, ranging from 10% to 90%, which is a critical consideration in pharmacokinetic studies.

• Safety & Toxicology: Yohimbine's therapeutic window is narrow. Common side effects in research models include insomnia, anxiety, palpitations, sweating, and hypertension. Overdose can cause severe hypotension, tachycardia, seizures, paralysis, and coma, and deaths from overdose have been reported. It is also associated with a risk of drug interactions, particularly with other stimulants.

• Regulatory Context: Dietary supplements containing yohimbe bark or yohimbine are banned in several countries, including Canada, Australia, the Netherlands, and the United Kingdom, due to potential health risks. This regulatory environment underscores its status as a potent pharmacological tool requiring careful handling in research settings.